Royalty Pharma plc Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest
Royalty Pharma plc (RPRX) reported Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest of $1.33 billion for the 12-month period ending 2024-12-31, per its 10-K filed 2025-02-12.
Financial Statements › Income Statement › Unrealized Gains
us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest · last filed 2025-02-12
- Royalty Pharma plc comprehensive income (loss), net of tax, including portion attributable to noncontrolling interest for the quarter ending 2023-12-31 was $717.59M.
- Royalty Pharma plc comprehensive income (loss), net of tax, including portion attributable to noncontrolling interest for the quarter ending 2023-09-30 was $122.08M, a 46.07% decline year-over-year.
- Royalty Pharma plc comprehensive income (loss), net of tax, including portion attributable to noncontrolling interest for the quarter ending 2023-06-30 was $351.34M, a 28.73% decline year-over-year.
- Royalty Pharma plc comprehensive income (loss), net of tax, including portion attributable to noncontrolling interest for the quarter ending 2023-03-31 was $509.09M, a 321.59% increase year-over-year.
- Royalty Pharma plc comprehensive income (loss), net of tax, including portion attributable to noncontrolling interest for fiscal 2024 was $1.33B, a 21.72% decline from fiscal 2023.
- Royalty Pharma plc comprehensive income (loss), net of tax, including portion attributable to noncontrolling interest for fiscal 2023 was $1.70B, a 747.37% increase from fiscal 2022.
- Royalty Pharma plc comprehensive income (loss), net of tax, including portion attributable to noncontrolling interest for fiscal 2022 was $200.63M, a 83.31% decline from fiscal 2021.
- Royalty Pharma plc comprehensive income (loss), net of tax, including portion attributable to noncontrolling interest for fiscal 2021 was $1.20B, a 32.04% decline from fiscal 2020.
| Period end | Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest 3 month | Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest 3 month as first filed | Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest 6 month | Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest 9 month | Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest 12 month | Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest 12 month as first filed |
|---|---|---|---|---|---|---|
| 2024-12-31 | $1.33B 10-K · filed 2025-02-12 | |||||
| 2023-12-31 | $717.59M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-12 | $839.66M derived: sum of 2 quarters · filed 2025-02-12 | $1.19B derived: sum of 3 quarters · filed 2025-02-12 | $1.70B 10-K · filed 2025-02-12 | ||
| 2023-09-30 | $122.08M 10-Q · filed 2023-11-08 | $473.41M derived: sum of 2 quarters · filed 2023-11-08 | $982.50M 10-Q · filed 2023-11-08 | $343.09M derived: sum of 4 quarters · filed 2025-02-12 | ||
| 2023-06-30 | $351.34M 10-Q · filed 2023-08-08 | $860.42M 10-Q · filed 2023-08-08 | $221.02M derived: sum of 3 quarters · filed 2025-02-12 | $447.37M derived: sum of 4 quarters · filed 2025-02-12 | ||
| 2023-03-31 | $509.09M 10-Q · filed 2023-05-09 | -$130.32M derived: sum of 2 quarters · filed 2025-02-12 | $96.03M derived: sum of 3 quarters · filed 2025-02-12 | $588.97M derived: sum of 4 quarters · filed 2025-02-12 | ||
| 2022-12-31 | -$639.41M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-12 | -$413.06M derived: sum of 2 quarters · filed 2025-02-12 | $79.88M derived: sum of 3 quarters · filed 2025-02-12 | $200.63M 10-K · filed 2025-02-12 | ||
| 2022-09-30 | $226.35M 10-Q · filed 2023-11-08 | $719.29M derived: sum of 2 quarters · filed 2023-11-08 | $840.04M 10-Q · filed 2023-11-08 | $886.39M derived: sum of 4 quarters · filed 2024-02-15 | ||
| 2022-06-30 | $492.93M 10-Q · filed 2023-08-08 | $613.69M 10-Q · filed 2023-08-08 | $660.03M derived: sum of 3 quarters · filed 2024-02-15 | $867.50M derived: sum of 4 quarters · filed 2024-02-15 | ||
| 2022-03-31 | $120.75M 10-Q · filed 2023-05-09 | $167.10M derived: sum of 2 quarters · filed 2024-02-15 | $374.56M derived: sum of 3 quarters · filed 2024-02-15 | $1.17B derived: sum of 4 quarters · filed 2024-02-15 | ||
| 2021-12-31 | $46.35M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-15 | $253.81M derived: sum of 2 quarters · filed 2024-02-15 | $1.05B derived: sum of 3 quarters · filed 2024-02-15 | $1.20B 10-K · filed 2024-02-15 | ||
| 2021-09-30 | $207.47M 10-Q · filed 2022-11-08 | $1.01B derived: sum of 2 quarters · filed 2022-11-08 | $1.16B 10-Q · filed 2022-11-08 | $2.05B derived: sum of 4 quarters · filed 2023-02-15 | ||
| 2021-06-30 | $799.48M 10-Q · filed 2022-08-04 | $948.09M 10-Q · filed 2022-08-04 | $1.84B derived: sum of 3 quarters · filed 2023-02-15 | $2.14B derived: sum of 4 quarters · filed 2023-02-15 | ||
| 2021-03-31 | $148.61M 10-Q · filed 2022-05-05 | $58.75M 10-Q · filed 2021-05-11 | $1.04B derived: sum of 2 quarters · filed 2023-02-15 | $1.34B derived: sum of 3 quarters · filed 2023-02-15 | $1.79B derived: sum of 4 quarters · filed 2023-02-15 | |
| 2020-12-31 | $893.33M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-15 | $1.19B derived: sum of 2 quarters · filed 2023-02-15 | $1.64B derived: sum of 3 quarters · filed 2023-02-15 | $1.77B 10-K · filed 2023-02-15 | $1.04B 10-K · filed 2021-02-24 | |
| 2020-09-30 | $298.20M 10-Q · filed 2020-11-12 | $747.23M derived: sum of 2 quarters · filed 2020-11-12 | $875.26M 10-Q · filed 2020-11-12 | $2.42B derived: sum of 4 quarters · filed 2022-02-15 | ||
| 2020-06-30 | $449.02M 10-Q · filed 2020-08-12 | $577.05M 10-Q · filed 2020-08-12 | $2.12B derived: sum of 3 quarters · filed 2022-02-15 | $2.53B derived: sum of 4 quarters · filed 2022-02-15 | ||
| 2020-03-31 | $128.03M 10-Q · filed 2021-05-11 | $1.67B derived: sum of 2 quarters · filed 2022-02-15 | $2.08B derived: sum of 3 quarters · filed 2022-02-15 | $2.23B derived: sum of 4 quarters · filed 2022-02-15 | ||
| 2019-12-31 | $1.54B derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-15 | $1.95B derived: sum of 2 quarters · filed 2022-02-15 | $2.10B derived: sum of 3 quarters · filed 2022-02-15 | $2.47B 10-K · filed 2022-02-15 | $2.36B 10-K · filed 2021-02-24 | |
| 2019-09-30 | $407.70M 10-Q · filed 2020-11-12 | $563.96M derived: sum of 2 quarters · filed 2020-11-12 | $932.99M 10-Q · filed 2020-11-12 | |||
| 2019-06-30 | $156.25M 10-Q · filed 2020-08-12 | $525.28M 10-Q · filed 2020-08-12 | ||||
| 2018-12-31 | $983.23M 10-K · filed 2021-02-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |